<DOC>
	<DOCNO>NCT02092792</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I study evaluate safety , tolerability , PK escalate dos DLYE5953A administer patient incurable , locally advanced , metastatic solid malignancy progress standard therapy . The Phase I study consist two stage : Stage 1 dose-escalation Stage 2 expansion select patient . In Stage 1 , 3 + 3 dose-escalation design use examine safety , tolerability , PK increase dos DLYE5953A . In Stage 2 , patient enrol characterize safety , tolerability , PK propose dose schedule future study .</brief_summary>
	<brief_title>A Study Evaluating Safety Escalating Doses DLYE5953A Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Age &gt; /= 18 year ECOG performance status 0 1 Histologically cytologically document advanced metastatic solid tumor establish therapy either exist proven ineffective intolerable Measurable disease RECIST v1.1 least one measurable target lesion Treatment chemotherapy , hormonal therapy ( except hormone replacement therapy , oral contraceptive ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) , herbal therapy cancer therapy within 4 week prior initiation DLYE5953A Oral kinase inhibitor approve local regulatory authority may use within 2 week prior initiation DLYE5953A , provide clinically relevant drugrelated toxicity completely resolve prior approval obtain Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>